Shares of HCW Biologics dropped 15.2% to $0.95 after the company announced its board approved a 1-for-6 reverse stock split, effective June 30, 2026 — the second such maneuver in barely a year. The company had previously completed a 1-for-40 reverse stock split on April 11, 2025 , meaning HCWB has now compressed its share count by a combined factor of 240-to-1 in that span. For investors, the math is brutal: what was once 240 shares is now one.
• A Second Split Signals Chronic Listing Trouble, Not a Fix
The reverse split will reduce shares outstanding from roughly 9.58 million to approximately 1.60 million. Post-split, the stock needs to hold above $6.00 just to stay equivalent to the pre-split $1.00 floor. Nasdaq's panel is allowing the company to remain listed only if it maintains a $1.00 bid price by July 29, 2026 — and warned that any new deficiency before September 22 would trigger immediate delisting. The margin for error is razor-thin.
• The Stock Already Met the $1 Threshold — So Why Split Now?
After Nasdaq's May 29 decision letter required 20 consecutive days above $1.00, the stock achieved that milestone by June 12 and has traded around $1 since.
The reverse split is intended to ensure compliance with the bid-price rule "as well as other conditions required by the Panel." In plain terms, HCWB barely cleared the bar and the board is buying a buffer — but at the cost of shattering trader confidence today.
• A Market Cap Under $12 Million Leaves Almost No Room to Raise Cash
HCWB's market cap sits at roughly $11.7 million.
Regaining compliance "does not remove underlying challenges such as prior going-concern language, dependence on external capital, and past use of warrant-based financings."
The company has warrants outstanding tied to a $17.4 million Armistice Capital investment, exercisable for up to 5.5 million shares at $0.6055 each — terms that will be adjusted post-split but still represent massive potential dilution relative to the tiny float.
• The Core Drug Story Is Overshadowed by Survival Mechanics HCWB is developing experimental immune-system drugs for autoimmune diseases and cancer. But with two reverse splits in 14 months, a sub-$12 million valuation, and a Nasdaq delisting sword hanging overhead, the clinical pipeline is secondary to the existential question: can this company stay public long enough for science to matter?